My Account
About Us
Contact us
الواجهة العربية
Medical News Medical News
Aricles Articles
Events Events
Guidelines Guidelines
Videos Library Videos Library
Diseases Diseases
Follow us : facebook twitter Digg Linkedin Boxiz

Please select the categories you are intersted in:
News Articles Guidelines Events Videos Journals' abstracts

Latest Subscribers
Advanced Search »



You must sign in to use this servcie

Feedback - Please use the form below to send your query or comment

You must sign in to use this servcie




Type 2 diabetes mellitus


Severe or life-threatening hyperglycaemia, severe liver or renal failure, type 1 diabetes, diabetic ketoacidosis with or without coma, patients with severe infection or trauma.

Adverse reactions:

Hypoglycaemia; cholestatic jaundice; agranulocytosis; aplastic anaemia; haemolytic anaemia. Blood dyscrasias (reversible), liver dysfunction, hypoglycaemia, GI symptoms, allergic skin reactions. Potentially Fatal: Prolonged hypoglycaemia seen in elderly or debilitated patients with hepatic or renal diseases.


Increased risk of hypoglycaemia when used with β-blockers. Additive hypoglycaemic effect with insulin and other antidiabetic drugs. Metabolism may be reduced by chloramphenicol and cimetidine. Increased hypoglycemic effect when used with cyclic antidepressants, pegvisomant, corticosteroids, salicylates, sulfonamide derivatives (except sulfacetamide) or fibric acid derivatives. Concurrent use may increase serum levels of ciclosporin. Increased serum levels when used with fluconazole. Metabolism of glibenclamide may be increased when used with rifampin. Concurrent use with coumarin derivatives may cause changes in INR. Concurrent admin with chloestyramine resin may lead to reduced absorption of glibenclamide. Serum levels may be reduced by colesevelam. Therapeutic efficacy may be diminished by luteinizing-hormone releasing hormone analogs. Concurrent use may increase adverse effects of phenytoin. Quinolone antibiotics may affect the efficacy of glibenclamide; monitor blood sugar levels. Hypoglycaemic effect may be reduced by somatropin. Potentially Fatal: Increased risk of liver toxicity when used with bosentan; avoid concurrent use.


Elderly; malnourished; mild to moderate renal and hepatic disorders. Impaired alertness. Avoid alcohol. Careful monitoring of blood-glucose concentration. Adrenocortical insufficiency. Changes in diet or prolonged exercise may also provoke hypoglycaemia. Increased risk of hypoglcaemia due to its long half-life. Avoid in severe hepatic impairment. Pregnancy, lactation.



Dosage and Administration

You must sign in to use this servcie

Technical Description

You must sign in to use this servcie

Forgot your password

sign up

Consultants Corner

Yaser Habrawi , F.R.C.S.Ed

Yaser Habrawi , F.R.C.S.Ed Consultant Ophthalmologist

Samir Moussa M.D.

Samir Moussa M.D. ENT Specialist

Dr. Talal Sabouni


Dr. Hani Najjar

Dr. Hani Najjar Pediatrics, Neurology

Dr. Faisal Dibsi

Dr. Faisal Dibsi Specialist of Otolaryngology - Head and Neck Surgery

Dr. Samer Al-Jneidy

Dr. Samer Al-Jneidy Pediatrician

Dr. Tahsin Martini

Dr. Tahsin Martini Degree status: M.D. in Ophthalmology

Dr . Dirar Abboud

Dr . Dirar Abboud Hepatologist – Gastroenterologist

Which of the following you are mostly interested in?

Cancer Research
Mental Health
Heart Disease & Diabetes
Sexual Health
Obesity and Healthy Diets
Mother & Child Health

Disclaimer : This site does not endorse or recommend any medical treatment, pharmaceuticals or brand names. More Details